Compare AstraZeneca plc (AZN) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs MasterCard Inc — how do they compare? AstraZeneca plc trades at $158.3 (market cap $250.84B), while MasterCard Inc trades at $559.99 (market cap $493.34B). The key difference: MasterCard Inc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| AZN | MA | |
|---|---|---|
Market Cap | $250.84B | $493.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $598.96 |
52-Week Low | $147.06 | $471.55 |
Enterprise Value | $278.12B | $506.38B |
Dividend Yield | 1.97% | 0.62% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
Mastercard (MA) trades at $563.17, up 0.04% today, with a bullish technical signal and strong institutional buying. The stock shows robust fundamentals, with revenue growing from $22.2B in 2022 to $32.8B in 2025 and net income margins above 45%. Recent earnings beats and a consensus price target of $660.85 reflect optimism, though high valuation ratios like a P/E of 30.98 warrant caution.
Outlook is positive due to consistent earnings growth, expanding digital payment initiatives, and analyst buy ratings. Risks include competitive pressures from new payment technologies and regulatory scrutiny. The stock offers upside potential but requires monitoring of valuation and market shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
